KLF4/MLL3复合物轴驱动NRBP2转录抑制急性髓系白血病细胞
该研究在急性髓系白血病(AML)中鉴定转录因子KLF4为生长抑制因子,其过表达显著损害AML细胞增殖。机制上KLF4与MLL3/KMT2C组蛋白甲基转移酶复合物互作激活NRBP2转录,进而抑制促白血病效应因子TNIK。TNIK-IN-1药理抑制TNIK可抑制AML细胞生长且对正常造血细胞影响有限,提示TNIK抑制是AML潜在治疗策略。
要点
- KLF4过表达通过MLL3复合物激活NRBP2转录,抑制AML细胞增殖。
- KLF4-NRBP2轴下游抑制促白血病因子TNIK。
- TNIK-IN-1抑制TNIK可抑制AML细胞生长,对正常造血细胞影响有限。
核心结论
- KLF4/MLL3复合物-NRBP2轴通过抑制TNIK表达限制AML生长,TNIK抑制是AML潜在治疗策略。
研究设计与样本
- 基础研究:在AML细胞中过表达KLF4,结合转录组与功能分析鉴定下游效应因子。
主要发现
- KLF4过表达显著损害AML细胞增殖。
- KLF4与MLL3/KMT2C组蛋白甲基转移酶复合物互作,激活NRBP2转录。
- 整合转录组与功能分析鉴定TNIK为KLF4-NRBP2轴抑制的促白血病下游效应因子。
- TNIK-IN-1抑制TNIK可抑制AML细胞生长,对正常造血细胞影响有限。
临床怎么用
- TNIK抑制可能作为AML治疗策略,尚需进一步临床前评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Acute myeloid leukemia (AML) is a heterogeneous malignancy rooted in hematopoietic stem cell dysregulation. Here, we identify the transcription factor Krüppel-like factor 4 (KLF4) as a potent suppressor of AML growth, with KLF4 overexpression markedly impairing AML cell proliferation. Mechanistically, KLF4 interacts with the lysine methyltransferase 2 C (MLL3/KMT2C) histone methyltransferase complex to activate transcription of nuclear receptor-binding protein 2 (NRBP2), a pseudokinase. Furthermore, integrated transcriptomic and functional analyses identify TNIK (TRAF2- and NCK-interacting kinase) as a pro-leukemic downstream effector restrained by the KLF4-NRBP2 axis. Pharmacological inhibition of TNIK with TNIK-IN-1 inhibits AML cell growth while exerting limited effects on normal hematopoietic cells. Together, these findings establish a KLF4/MLL3 complex-NRBP2 regulatory axis that restrains AML growth through suppression of TNIK expression and provide a rationale for further preclinical evaluation of TNIK inhibition as a therapeutic strategy in AML. Schematic model illustrating the mechanism by which the KLF4/MLL3 complex/NRBP2 axis regulates the progression of AML. In AML cells with basal KLF4 expression, higher expression of TNIK promotes the proliferation of AML cells (upper). Upon KLF4 overexpression, the TRD and ZnF domains of KLF4 bind to MLL3, which facilitates the recruitment of the MLL3 complex to the NRBP2 cis-regulatory regions. This activates NRBP2 transcription and subsequently downregulates TNIK expression, leading to the suppression of AML cell proliferation. Pharmacological inhibition of TNIK by TNIK-IN-1 reduces TNIK protein levels, represses AML cell growth, and induces cell apoptosis (lower). This study reveals a molecular mechanism by which KLF4 governs AML progression, providing a novel therapeutic target and a potential small-molecule inhibitor for AML treatment (Created in BioRender. he, Y. (2026) https://BioRender.com/q0q3j3q ).
引用
- Yang M, Lu T, He Y, et al. KLF4/MLL3 complex axis drives NRBP2 transcription to eliminate acute myeloid leukemia cells. Leukemia. 2026. PMID: 42686832. doi:10.1038/s41375-026-03117-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。